SMALL  	SMALL  	 NNP	O
CELL  	CELL  	 NNP	B-NP
CARCINOMA  	CARCINOMA  	 NNP	I-NP
OF  	OF  	 IN	I-NP
THE  	THE  	 DT	I-NP
PROSTATE 	PROSTATE 	 NNP	I-NP
:  	:  	 :	O
A  	A  	 DT	O
CASE  	CASE  	 NN	B-NP
REPORT  	REPORT  	 NN	I-NP
OF  	OF  	 IN	O
RELATIVE  	RELATIVE  	 NNP	O
LONG-TERM  	LONG-TERM  	 NNP	O
SURVIVAL  	SURVIVAL  	 NNP	O
Small  	Small  	 NNP	B-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
prostate  	prostate  	 NN	I-NP
( 	( 	 -LRB-	O
SCCP 	SCCP 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
rare 	rare 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
no  	no  	 DT	O
standard  	standard  	 JJ	O
treatment  	treatment  	 NN	B-NP
regimen  	regimen  	 NN	I-NP
has  	has  	 VBZ	O
yet  	yet  	 RB	O
been  	been  	 VBN	O
established 	established 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
overall  	overall  	 JJ	O
prognosis  	prognosis  	 NN	O
remains  	remains  	 VBZ	O
poor 	poor 	 JJ	O
.  	.  	 .	O
We  	We  	 PRP	O
experienced  	experienced  	 VBD	O
a  	a  	 DT	O
case  	case  	 NN	O
who  	who  	 WP	O
obtained  	obtained  	 VBD	O
relative  	relative  	 JJ	B-NP
long-term  	long-term  	 JJ	I-NP
survival  	survival  	 NN	I-NP
with  	with  	 IN	O
two  	two  	 CD	O
types  	types  	 NNS	O
of  	of  	 IN	O
chemotherapy  	chemotherapy  	 JJ	B-NP
treatments 	treatments 	 NNS	I-NP
.  	.  	 .	O
A  	A  	 DT	O
69-year-old  	69-year-old  	 JJ	O
man  	man  	 NN	O
underwent  	underwent  	 VBD	O
combined  	combined  	 VBN	B-NP
androgen  	androgen  	 JJ	I-NP
blockade  	blockade  	 NN	I-NP
( 	( 	 -LRB-	O
CAB 	CAB 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
a  	a  	 DT	O
diagnosis  	diagnosis  	 NN	O
of  	of  	 IN	O
prostate  	prostate  	 JJ	B-NP
adenocarcinoma  	adenocarcinoma  	 NNS	I-NP
( 	( 	 -LRB-	O
Gleason  	Gleason  	 NNP	B-NP
score  	score  	 NN	I-NP
=  	=  	 SYM	O
5  	5  	 CD	O
+  	+  	 CD	O
3 	3 	 CD	O
)  	)  	 -RRB-	O
that  	that  	 WDT	O
was  	was  	 VBD	O
staged  	staged  	 VBN	O
T3bN1M1b  	T3bN1M1b  	 NNP	O
( 	( 	 -LRB-	O
initial  	initial  	 JJ	O
PSA  	PSA  	 NNP	B-NP
=  	=  	 SYM	O
352  	352  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml 	ml 	 CD	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Twenty-five  	Twenty-five  	 CD	O
months  	months  	 NNS	O
after  	after  	 IN	O
hormonal  	hormonal  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
level  	level  	 NN	O
of  	of  	 IN	O
serum  	serum  	 JJ	B-NP
PSA  	PSA  	 NNP	I-NP
had  	had  	 VBD	O
elapsed  	elapsed  	 RB	O
remain  	remain  	 VB	O
low 	low 	 JJ	O
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
FDG-PET 	FDG-PET 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
CT  	CT  	 NNP	I-NP
revealed  	revealed  	 VBD	O
high  	high  	 JJ	O
value  	value  	 NN	O
at  	at  	 IN	O
the  	the  	 DT	O
lymph  	lymph  	 JJ	B-NP
node  	node  	 NN	I-NP
of  	of  	 IN	I-NP
para-aortic  	para-aortic  	 JJ	I-NP
and  	and  	 CC	O
pelvic  	pelvic  	 JJ	B-NP
lesion 	lesion 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
serum  	serum  	 JJ	B-NP
NSE  	NSE  	 NNP	I-NP
and  	and  	 CC	O
Pro-GRP  	Pro-GRP  	 JJ	B-NP
elevated 	elevated 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
a  	a  	 DT	O
prostate  	prostate  	 JJ	B-NP
re-biopsy  	re-biopsy  	 NN	I-NP
revealed  	revealed  	 VBD	O
a  	a  	 DT	O
small  	small  	 JJ	O
cell  	cell  	 NN	B-NP
carcinoma 	carcinoma 	 NN	I-NP
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
he  	he  	 PRP	O
was  	was  	 VBD	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
12-cycles  	12-cycles  	 CD	O
of  	of  	 IN	O
combination  	combination  	 NN	B-NP
chemotherapy  	chemotherapy  	 VBZ	I-NP
consisting  	consisting  	 VBG	O
of  	of  	 IN	O
etoposide  	etoposide  	 NN	B-NP
and  	and  	 CC	O
carboplatin 	carboplatin 	 NN	B-NP
.  	.  	 .	O
Then 	Then 	 RB	O
,  	,  	 ,	O
disease  	disease  	 NN	O
has  	has  	 VBZ	O
progressed 	progressed 	 VBN	O
,  	,  	 ,	O
so  	so  	 RB	O
he  	he  	 PRP	O
was  	was  	 VBD	O
changed  	changed  	 VBN	O
to  	to  	 TO	O
second  	second  	 JJ	O
line  	line  	 NN	B-NP
chemotherapy  	chemotherapy  	 NN	I-NP
with  	with  	 IN	O
amrubicin 	amrubicin 	 NN	B-NP
.  	.  	 .	O
He  	He  	 PRP	O
underwent  	underwent  	 VBD	O
12-cycles  	12-cycles  	 CD	O
chemotherapy  	chemotherapy  	 NN	O
with  	with  	 IN	O
amrubicin 	amrubicin 	 NN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
he  	he  	 PRP	O
died  	died  	 VBD	O
of  	of  	 IN	O
cancer  	cancer  	 NN	O
39  	39  	 CD	O
months  	months  	 NNS	O
after  	after  	 IN	O
the  	the  	 DT	O
initial  	initial  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
SCCP 	SCCP 	 NNP	B-NP
.  	.  	 .	O
